John C Lieske

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2491782/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. American Journal of Kidney Diseases, 2023, 81, 145-155.e1.	1.9	21
2	Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2. Nephrology Dialysis Transplantation, 2022, 37, 869-875.	0.7	23
3	Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report. American Journal of Kidney Diseases, 2022, 79, 125-128.	1.9	10
4	National Kidney Foundation Laboratory Engagement Working Group Recommendations for Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories. Clinical Chemistry, 2022, 68, 511-520.	3.2	70
5	Primary hyperoxaluria type 1: novel therapies at a glance. CKJ: Clinical Kidney Journal, 2022, 15, i17-i22.	2.9	10
6	Clinical Impact of the Refit CKD-EPI 2021 Creatinine-Based eGFR Equation. Clinical Chemistry, 2022, 68, 534-539.	3.2	49
7	Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series. Kidney Medicine, 2022, 4, 100419.	2.0	8
8	Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 414-422.	4.5	3
9	Comparison of clinical features of pregnant and non-pregnant females with primary hyperoxaluria. Journal of Nephrology, 2022, , 1.	2.0	0
10	New Insights Regarding Organ Transplantation in Primary Hyperoxaluria Type 1. Kidney International Reports, 2022, 7, 146-148.	0.8	0
11	Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. Genetics in Medicine, 2022, 24, 654-662.	2.4	30
12	Nephrotoxin Exposure in the 3 Years following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease among Acute Kidney Injury Survivors. American Journal of Nephrology, 2022, 53, 273-281.	3.1	7
13	Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1. Kidney International Reports, 2022, 7, 494-506.	0.8	15
14	Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1. American Journal of Kidney Diseases, 2022, 80, 373-382.	1.9	2
15	A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate. Kidney International Reports, 2022, 7, 1690-1693.	0.8	3
16	The genetics of kidney stone disease and nephrocalcinosis. Nature Reviews Nephrology, 2022, 18, 224-240.	9.6	57
17	FC070: Lumasiran for Patients with Primary Hyperoxaluria Type 1 with Impaired Kidney Function: Data from the 6-Month Analysis of the Phase 3 Illuminate-C Trial. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0

18 Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria. , 2022, 1, .

8

#	Article	IF	CITATIONS
19	Pathophysiology and Treatment of Enteric Hyperoxaluria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 487-495.	4.5	63
20	The Case An unusual cause of tender skin lesion in an end-stage kidney disease patient. Kidney International, 2021, 99, 275-276.	5.2	0
21	CYP24A1 deficiency causing persistent hypercalciuria in a stone former. Journal of Nephrology, 2021, 34, 949-951.	2.0	1
22	A Target Antigen–Based Approach to the Classification of Membranous Nephropathy. Mayo Clinic Proceedings, 2021, 96, 577-591.	3.0	45
23	Automated radiomic analysis of CT images to predict likelihood of spontaneous passage of symptomatic renal stones. Emergency Radiology, 2021, 28, 781-788.	1.8	6
24	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	1.7	3
25	Has Noninvasive Kidney Transplant Surveillance Finally Arrived?. Clinical Chemistry, 2021, 67, 1047-1049.	3.2	0
26	Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis. Frontiers in Medicine, 2021, 8, 592357.	2.6	6
27	Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. New England Journal of Medicine, 2021, 384, 1216-1226.	27.0	265
28	Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. Kidney International Reports, 2021, 6, 1022-1031.	0.8	54
29	Human kidney stones: a natural record of universal biomineralization. Nature Reviews Urology, 2021, 18, 404-432.	3.8	27
30	MO047STABLE EGFR IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 TREATED WITH LUMASIRAN, REGARDLESS OF KIDNEY FUNCTION AT START OF TREATMENT. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
31	Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1025-1036.	4.5	48
32	Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases. American Journal of Kidney Diseases, 2021, 77, 816-819.	1.9	11
33	FC 013LUMASIRAN DEMONSTRATED COMPARABLE OXALATE REDUCTION AND SAFETY IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
34	Excretion of urine extracellular vesicles bearing markers of activated immune cells and calcium/phosphorus physiology differ between calcium kidney stone formers and non-stone formers. BMC Nephrology, 2021, 22, 204.	1.8	13
35	Genomics Integration Into Nephrology Practice. Kidney Medicine, 2021, 3, 785-798.	2.0	13
36	High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency. Kidney International Reports, 2021, 6, 1895-1903.	0.8	8

#	Article	IF	CITATIONS
37	Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function. American Journal of Transplantation, 2021, , .	4.7	2
38	Surgical interventions for symptomatic urinary stones during pregnancy. Chinese Medical Journal, 2021, 134, 1994-1996.	2.3	1
39	Establishing a nephrology genetic clinic. Kidney International, 2021, 100, 254-259.	5.2	14
40	1H Nuclear Magnetic Resonance Spectroscopy-Based Methods for the Quantification of Proteins in Urine. Analytical Chemistry, 2021, 93, 13177-13186.	6.5	2
41	Risk of Symptomatic Kidney Stones During and After Pregnancy. American Journal of Kidney Diseases, 2021, 78, 409-417.	1.9	15
42	Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. Kidney International Reports, 2021, 6, 2862-2884.	0.8	15
43	Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia. Nephrology Dialysis Transplantation, 2021, 36, 945-948.	0.7	13
44	Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria. Nephrology Dialysis Transplantation, 2021, 36, 2208-2215.	0.7	8
45	In Vivo Entombment of Bacteria and Fungi during Calcium Oxalate, Brushite, and Struvite Urolithiasis. Kidney360, 2021, 2, 298-311.	2.1	14
46	Genotype Phenotype Correlation in Dent Disease 2 and Review of the Literature: OCRL Gene Pleiotropism or Extreme Phenotypic Variability of Lowe Syndrome?. Genes, 2021, 12, 1597.	2.4	8
47	End Points for Clinical Trials in Hyperoxaluria: Case Study of Patient-Focused Drug Development in a Rare Disease. American Journal of Kidney Diseases, 2021, , .	1.9	0
48	Microsporidium Infection–Associated Acute Kidney Injury in a Patient With HIV. Kidney Medicine, 2021, 4, 100390.	2.0	1
49	Clinical Outcomes and Histological Patterns in Oxalate Nephropathy due to Enteric and Nonenteric Risk Factors. American Journal of Nephrology, 2021, 52, 961-968.	3.1	4
50	Estimating Glomerular Filtration Rate from Serum Myo-Inositol, Valine, Creatinine and Cystatin C. Diagnostics, 2021, 11, 2291.	2.6	9
51	Comparison of high glomerular filtration rate thresholds for identifying hyperfiltration. Nephrology Dialysis Transplantation, 2020, 35, 1017-1026.	0.7	14
52	Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts. Pediatric Nephrology, 2020, 35, 633-640.	1.7	14
53	GeoBioMed sheds new light on human kidney stone crystallization and dissolution. Nature Reviews Urology, 2020, 17, 1-2.	3.8	19
54	Clâ^' and H+ coupling properties and subcellular localizations of wildtype and disease-associated variants of the voltage-gated Clâ^'/H+ exchanger ClC-5. Journal of Biological Chemistry, 2020, 295, 1464-1473.	3.4	8

#	Article	IF	CITATIONS
55	Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. Kidney International, 2020, 97, 786-792.	5.2	13
56	Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity. Kidney International Reports, 2020, 5, 2021-2031.	0.8	13
57	Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones. Orphanet Journal of Rare Diseases, 2020, 15, 319.	2.7	15
58	Patterns of Cystatin C Uptake and Use Across and Within Hospitals. Mayo Clinic Proceedings, 2020, 95, 1649-1659.	3.0	10
59	Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	5
60	Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function. Journal of the American Society of Nephrology: JASN, 2020, 31, 2642-2652.	6.1	30
61	Genome-Wide Association Meta-Analysis of Individuals of European Ancestry Identifies Suggestive Loci for Sodium Intake, Potassium Intake, and Their Ratio Measured from 24-Hour or Half-Day Urine Samples. Journal of Nutrition, 2020, 150, 2635-2645.	2.9	4
62	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	2.9	14
63	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	6.2	12
64	Diagnostic Imaging for Kidney Stones—Reply. JAMA - Journal of the American Medical Association, 2020, 324, 1465.	7.4	1
65	Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical) AGXT Gene Mutation. Kidney International Reports, 2020, 5, 955-958.	0.8	20
66	Plasma oxalate: comparison of methodologies. Urolithiasis, 2020, 48, 473-480.	2.0	16
67	Management of Kidney Stones in 2020. JAMA - Journal of the American Medical Association, 2020, 323, 1961.	7.4	44
68	Risk Factors for Acute Kidney Injury in Hospitalized Non–Critically Ill Patients: AÂPopulation-Based Study. Mayo Clinic Proceedings, 2020, 95, 459-467.	3.0	12
69	Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria. BMC Nephrology, 2020, 21, 133.	1.8	4
70	End Points for Clinical Trials in Primary Hyperoxaluria. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1056-1065.	4.5	51
71	Tubular secretion of creatinine and kidney function: an observational study. BMC Nephrology, 2020, 21, 108.	1.8	26
72	Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort. International Journal of Molecular Sciences, 2020, 21, 3608.	4.1	20

#	Article	IF	CITATIONS
73	Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria. ELife, 2020, 9, .	6.0	45
74	Clinician perspectives on inpatient cystatin C utilization: A qualitative case study at Mayo Clinic. PLoS ONE, 2020, 15, e0243618.	2.5	5
75	Genome-wide meta-analysis of macronutrient intake of 91,114 European ancestry participants from the cohorts for heart and aging research in genomic epidemiology consortium. Molecular Psychiatry, 2019, 24, 1920-1932.	7.9	44
76	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 36-46.	27.0	324
77	Glomerular Volume and Glomerulosclerosis at Different Depths within the Human Kidney. Journal of the American Society of Nephrology: JASN, 2019, 30, 1471-1480.	6.1	39
78	Dent disease: A window into calcium and phosphate transport. Journal of Cellular and Molecular Medicine, 2019, 23, 7132-7142.	3.6	20
79	Urinary extracellular vesicle-associated MCP-1 and NGAL derived from specific nephron segments differ between calcium oxalate stone formers and controls. American Journal of Physiology - Renal Physiology, 2019, 317, F1475-F1482.	2.7	16
80	Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review. Mayo Clinic Proceedings, 2019, 94, 500-514.	3.0	42
81	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptorÂantibodies. Kidney International, 2019, 95, 429-438.	5.2	123
82	Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression. JAMA Internal Medicine, 2019, 179, 542.	5.1	78
83	Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient. American Journal of Kidney Diseases, 2019, 74, 417-420.	1.9	12
84	Antiurolithic activity and biotransformation of galloylquinic acids by Aspergillus alliaceus ATCC10060, Aspergillus brasiliensis ATCC 16404, and Cunninghamella elegans ATCC 10028b. Biocatalysis and Agricultural Biotechnology, 2019, 18, 101012.	3.1	7
85	Understanding, justifying, and optimizing radiation exposure for CT imaging in nephrourology. Nature Reviews Urology, 2019, 16, 231-244.	3.8	28
86	Serum levels of DNAJB9 are elevated in fibrillaryÂglomerulonephritis patients. Kidney International, 2019, 95, 1269-1272.	5.2	26
87	Genome-wide Association Study of 24-Hour Urinary Excretion of Calcium, Magnesium, and Uric Acid. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 448-460.	2.4	6
88	Automatic detection of calcium phosphate deposit plugs at the terminal ends of kidney tubules. Healthcare Technology Letters, 2019, 6, 271-274.	3.3	6
89	Uncovering a Novel Stone in 27 Patients: Calcium Tartrate Tetrahydrate. Urology, 2019, 126, 49-53.	1.0	4
90	Predictors of Symptomatic Kidney Stone Recurrence After the First and Subsequent Episodes. Mayo Clinic Proceedings, 2019, 94, 202-210.	3.0	70

6

#	Article	IF	CITATIONS
91	Heritable traits that contribute to nephrolithiasis. Urolithiasis, 2019, 47, 5-10.	2.0	10
92	Challenges in Measuring Glomerular Filtration Rate: A Clinical Laboratory Perspective. Advances in Chronic Kidney Disease, 2018, 25, 84-92.	1.4	24
93	The Synthesized Plant Metabolite 3,4,5-Tri- <i>O</i> Galloylquinic Acid Methyl Ester Inhibits Calcium Oxalate Crystal Growth in a <i>Drosophila</i> Model, Downregulates Renal Cell Surface Annexin A1 Expression, and Decreases Crystal Adhesion to Cells. Journal of Medicinal Chemistry, 2018, 61, 1609-1621.	6.4	18
94	The Changing Incidence and Presentation of Urinary Stones Over 3 Decades. Mayo Clinic Proceedings, 2018, 93, 291-299.	3.0	107
95	Bariatric Surgery and Kidney Health. Journal of the American Society of Nephrology: JASN, 2018, 29, 1085-1086.	6.1	5
96	Urinalysis for the diagnosis of glomerulonephritis: role of dysmorphic red blood cells. Nephrology Dialysis Transplantation, 2018, 33, 1397-1403.	0.7	23
97	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney International Reports, 2018, 3, 56-64.	0.8	109
98	Cystatin C Predicts Renal Recovery Earlier Than Creatinine Among Patients With Acute Kidney Injury. Kidney International Reports, 2018, 3, 337-342.	0.8	30
99	Inching toward a Greater Understanding of Genetic Hypercalciuria. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1460-1462.	4.5	2
100	Geobiology reveals how human kidney stones dissolve in vivo. Scientific Reports, 2018, 8, 13731.	3.3	50
101	Analytical performance of an immunoassay to measure proenkephalin. Clinical Biochemistry, 2018, 58, 72-77.	1.9	28
102	Clinical and Pathology Findings Associate Consistently with Larger Glomerular Volume. Journal of the American Society of Nephrology: JASN, 2018, 29, 1960-1969.	6.1	33
103	Impact of Serum Cystatin C–Based Glomerular Filtration Rate Estimates on Drug Dose Selection in Hospitalized Patients. Pharmacotherapy, 2018, 38, 1068-1073.	2.6	12
104	Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia. American Journal of Physiology - Renal Physiology, 2018, 314, F1062-F1076.	2.7	28
105	Risk of ESRD and Mortality in Kidney and Bladder Stone Formers. American Journal of Kidney Diseases, 2018, 72, 790-797.	1.9	72
106	Invited response to recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2. American Journal of Transplantation, 2018, 18, 527.	4.7	4
107	Editorial Comment. Journal of Urology, 2017, 197, 409-410.	0.4	0
108	Cystatin C–Guided Vancomycin Dosing in Critically III Patients: AÂQuality Improvement Project. American Journal of Kidney Diseases, 2017, 69, 658-666.	1.9	60

John C Lieske

#	Article	IF	CITATIONS
109	Longitudinal characterization of renal proximal tubular markers in normotensive and preeclamptic pregnancies. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 312, R773-R778.	1.8	12
110	Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index. Critical Care Medicine, 2017, 45, e23-e29.	0.9	179
111	No increase in the incidence of acute kidney injuryÂin a population-based annual temporalÂtrends epidemiology study. Kidney International, 2017, 92, 721-728.	5.2	57
112	Single-Nephron Glomerular Filtration Rate in Healthy Adults. New England Journal of Medicine, 2017, 376, 2349-2357.	27.0	247
113	Association of urinary citrate excretion, pH, and net gastrointestinal alkali absorption with diet, diuretic use, and blood glucose concentration. Physiological Reports, 2017, 5, e13411.	1.7	7
114	Polymorphisms in Renal Ammonia Metabolism Genes Correlate With 24-Hour Urine pH. Kidney International Reports, 2017, 2, 1111-1121.	0.8	8
115	Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clinical Biochemistry, 2017, 50, 1014-1019.	1.9	44
116	Probiotics for prevention of urinary stones. Annals of Translational Medicine, 2017, 5, 29-29.	1.7	41
117	Association between kidney intracapsular pressure and ultrasound elastography. Critical Care, 2017, 21, 251.	5.8	14
118	The first Sri Lankan family with Dent disease-1 due to a pathogenic variant in the CLCN5 gene: a case report. BMC Research Notes, 2017, 10, 539.	1.4	0
119	Standardization of Urine Albumin Measurements: Status and Performance Goals. journal of applied laboratory medicine, The, 2017, 2, 423-429.	1.3	13
120	Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. PLoS ONE, 2017, 12, e0186769.	2.5	14
121	Commentary. Clinical Chemistry, 2016, 62, 440-440.	3.2	0
122	Functional and transport analyses of <i>CLCN5</i> genetic changes identified in Dent disease patients. Physiological Reports, 2016, 4, e12776.	1.7	13
123	Digenic mutations of human OCRL paralogs in Dent's disease type 2 associated with Chiari I malformation. Human Genome Variation, 2016, 3, 16042.	0.7	8
124	Endoscopic and Pathologic Characterization of Papillary Architecture in Struvite Stone Formers. Urology, 2016, 90, 39-44.	1.0	9
125	Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations. Journal of Urology, 2016, 195, 1476-1481.	0.4	17
126	Editorial Comment. Journal of Urology, 2016, 196, 1147-1148.	0.4	0

#	Article	IF	CITATIONS
127	Glomerular Pathology in Dent Disease and Its Association with Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2168-2176.	4.5	47
128	The Influence of Processing and Storage Conditions on Renal Protein Biomarkers. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1726-1728.	4.5	11
129	Characterization of Inner Medullary Collecting Duct Plug Formation Among Idiopathic Calcium Oxalate Stone Formers. Urology, 2016, 94, 47-52.	1.0	6
130	Creatinine–Based and Cystatin C–Based GFR Estimating Equations and Their Non-GFR Determinants in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1640-1649.	4.5	33
131	The relatively poor correlation between random andÂ24-hour urine protein excretion in patients withÂbiopsy-proven glomerular diseases. Kidney International, 2016, 90, 1080-1089.	5.2	51
132	Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. Journal of Nephrology, 2016, 29, 715-734.	2.0	122
133	Kidney Function After the First Kidney Stone Event. Mayo Clinic Proceedings, 2016, 91, 1744-1752.	3.0	18
134	Specific renal parenchymalâ€derived urinary extracellular vesicles identify ageâ€associated structural changes in living donor kidneys. Journal of Extracellular Vesicles, 2016, 5, 29642.	12.2	55
135	Key influence of sex on urine volume and osmolality. Biology of Sex Differences, 2016, 7, 12.	4.1	19
136	Tubulointerstitial Fibrosis of Living Donor Kidneys Associates with Urinary Monocyte Chemoattractant Protein 1. American Journal of Nephrology, 2016, 43, 454-459.	3.1	10
137	Overestimation of Glomerular Filtration Rate Among Critically Ill Adults With Hospital-Acquired Oligoanuric Acute Kidney Injury. Journal of Pharmacy Practice, 2016, 29, 125-131.	1.0	9
138	Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. Journal of Nephrology, 2016, 29, 45-51.	2.0	13
139	Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 119-126.	4.5	81
140	Complete Remission in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 81-89.	4.5	53
141	Non-steroidal anti-inflammatory drugs for renal colic. Lancet, The, 2016, 387, 1971-1972.	13.7	6
142	Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. American Journal of Kidney Diseases, 2016, 68, 58-67.	1.9	78
143	Discordance Between Iothalamate and Iohexol UrinaryÂClearances. American Journal of Kidney Diseases, 2016, 67, 49-55.	1.9	52
144	Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis. Journal of Nephrology, 2016, 29, 211-219.	2.0	86

#	Article	IF	CITATIONS
145	Sex Steroid Hormone Levels May Not Explain Gender Differences in Development of Nephrolithiasis. Journal of Endourology, 2015, 29, 1341-1345.	2.1	5
146	Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrology, 2015, 16, 190.	1.8	14
147	Distinguishing age-related from disease-related glomerulosclerosis on kidney biopsy: the Aging Kidney Anatomy study. Nephrology Dialysis Transplantation, 2015, 30, 2034-2039.	0.7	90
148	Endoscopic and Histologic Findings in a Cohort of Uric Acid and Calcium Oxalate Stone Formers. Urology, 2015, 85, 771-776.	1.0	18
149	Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. Journal of the American Society of Nephrology: JASN, 2015, 26, 2559-2570.	6.1	185
150	Aqueous extract of Costus arabicus inhibits calcium oxalate crystal growth and adhesion to renal epithelial cells. Urolithiasis, 2015, 43, 119-124.	2.0	12
151	Risk of Acute Kidney Injury, Dialysis, and Mortality in Patients With Chronic Kidney Disease After Intravenous Contrast Material Exposure. Mayo Clinic Proceedings, 2015, 90, 1046-1053.	3.0	81
152	Fecal electrolyte testing for evaluation of unexplained diarrhea: Validation of body fluid test accuracy in the absence of a reference method. Clinical Biochemistry, 2015, 48, 1126-1130.	1.9	5
153	Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study. Biology of Sex Differences, 2015, 6, 2.	4.1	37
154	Kidney stones are common after bariatric surgery. Kidney International, 2015, 87, 839-845.	5.2	106
155	Performance of Cystatin C– and Creatinine-Based Estimated Glomerular Filtration Rate Equations Depends on Patient Characteristics. Clinical Chemistry, 2015, 61, 1265-1272.	3.2	44
156	Stone Composition Among First-Time Symptomatic Kidney Stone Formers in the Community. Mayo Clinic Proceedings, 2015, 90, 1356-1365.	3.0	93
157	Effect of Demographics on Excretion of Key Urinary Factors Related to Kidney Stone Risk. Urology, 2015, 86, 690-696.	1.0	17
158	Quantification of Asymptomatic Kidney Stone Burden by Computed Tomography for Predicting Future Symptomatic Stone Events. Urology, 2015, 85, 45-50.	1.0	41
159	Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney International, 2015, 87, 623-631.	5.2	63
160	SLC2A9 Genotype Is Associated with SLC2A9 Gene Expression and Urinary Uric Acid Concentration. PLoS ONE, 2015, 10, e0128593.	2.5	16
161	Altered Calcium and Vitamin D Homeostasis in First-Time Calcium Kidney Stone-Formers. PLoS ONE, 2015, 10, e0137350.	2.5	31
162	Sulfate but Not Thiosulfate Reduces Calculated and Measured Urinary Ionized Calcium and Supersaturation: Implications for the Treatment of Calcium Renal Stones. PLoS ONE, 2014, 9, e103602.	2.5	13

#	Article	IF	CITATIONS
163	Oxalate Quantification in Hemodialysate to Assess Dialysis Adequacy for Primary Hyperoxaluria. American Journal of Nephrology, 2014, 39, 376-382.	3.1	22
164	Secondarily Infected Nonstruvite Urolithiasis: A Prospective Evaluation. Urology, 2014, 84, 1295-1300.	1.0	21
165	Stone Composition as a Function of Age and Sex. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2141-2146.	4.5	200
166	Heritability of Urinary Traits That Contribute to Nephrolithiasis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 943-950.	4.5	30
167	State of the Art for Measurement of Urine Albumin: Comparison of Routine Measurement Procedures to Isotope Dilution Tandem Mass Spectrometry. Clinical Chemistry, 2014, 60, 471-480.	3.2	55
168	Distinguishing Characteristics of Idiopathic Calcium Oxalate Kidney Stone Formers with Low Amounts of Randall's Plaque. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1757-1763.	4.5	36
169	Gastric Bypass Surgery and Measured and Estimated GFR in Women. American Journal of Kidney Diseases, 2014, 64, 663-665.	1.9	35
170	The ROKS Nomogram for Predicting a Second Symptomatic Stone Episode. Journal of the American Society of Nephrology: JASN, 2014, 25, 2878-2886.	6.1	190
171	Looking for a Better Creatinine. Clinical Chemistry, 2014, 60, 1036-1039.	3.2	8
172	Thiazide Diuretic Prophylaxis for Kidney Stones and the Risk of Diabetes Mellitus. Journal of Urology, 2014, 192, 1700-1704.	0.4	14
173	Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Critical Care, 2014, 18, R110.	5.8	60
174	New Insights Regarding the Interrelationship of Obesity, Diet, Physical Activity, and Kidney Stones. Journal of the American Society of Nephrology: JASN, 2014, 25, 211-212.	6.1	15
175	Performance of Creatinine-Based GFR Estimating Equations inÂSolid-Organ Transplant Recipients. American Journal of Kidney Diseases, 2014, 63, 1007-1018.	1.9	103
176	Calcifying nanoparticles promote mineralization in vascular smooth muscle cells: implications for atherosclerosis. International Journal of Nanomedicine, 2014, 9, 2689.	6.7	21
177	Treatment of Cholesterol Embolization Syndrome in the Setting of an Acute Indication for Anticoagulation Therapy. Journal of Medical Cases, 2014, 5, 376-379.	0.7	9
178	Update on Oxalate Crystal Disease. Current Rheumatology Reports, 2013, 15, 340.	4.7	74
179	Hereditary causes of kidney stones and chronic kidney disease. Pediatric Nephrology, 2013, 28, 1923-1942.	1.7	213
180	Measurement of urinary TGF-β1 in patients with diabetes mellitus and normal controls. Clinical Biochemistry, 2013, 46, 1430-1435.	1.9	18

#	Article	IF	CITATIONS
181	Performance of flow cytometry to screen urine for bacteria and white blood cells prior to urine culture. Clinical Biochemistry, 2013, 46, 810-813.	1.9	33
182	Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. Kidney International, 2013, 83, 1169-1176.	5.2	119
183	Effect of Age on the Clinical Presentation of Incident Symptomatic Urolithiasis in the General Population. Journal of Urology, 2013, 189, 158-164.	0.4	56
184	Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. Nephrology Dialysis Transplantation, 2013, 28, 1175-1185.	0.7	71
185	Commentary. Clinical Chemistry, 2013, 59, 890-890.	3.2	0
186	A reference system for urinary albumin: current status. Clinical Chemistry and Laboratory Medicine, 2013, 51, 981-9.	2.3	33
187	Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney International, 2013, 84, 818-825.	5.2	62
188	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International, 2013, 83, 749-756.	5.2	268
189	Temporal Trends in Incidence of Kidney Stones Among Children: A 25-Year Population Based Study. Journal of Urology, 2012, 188, 247-252.	0.4	260
190	Controlled Metabolic Diet Reduces Calcium Oxalate Supersaturation but Not Oxalate Excretion After Bariatric Surgery. Urology, 2012, 80, 250-254.	1.0	29
191	Analytic and clinical validation of a standardized cystatin C particle enhanced turbidimetric assay (PETIA) to estimate glomerular filtration rate. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1591-6.	2.3	24
192	Genetic Causes of Kidney Stones and Kidney Failure. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 2-18.	0.8	7
193	Chronic Kidney Disease in Kidney Stone Formers. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2069-2075.	4.5	163
194	Shock Wave Lithotripsy is Not Predictive of Hypertension Among Community Stone Formers at Long-Term Followup. Journal of Urology, 2011, 185, 164-169.	0.4	51
195	Isolation, Propagation, and Analysis of Biological Nanoparticles. Methods in Molecular Biology, 2011, 790, 263-275.	0.9	1
196	1,2,3,4,6-Penta-O-galloyl-beta-D-glucose reduces renal crystallization and oxidative stress in a hyperoxaluric rat model. Kidney International, 2011, 79, 538-545.	5.2	37
197	Fat malabsorption and increased intestinal oxalate absorption are common after roux-en-Y gastric bypass surgery. Surgery, 2011, 149, 654-661.	1.9	152
198	The association of matrix Gla protein isomers with calcification in capsules surrounding silicone breast implants. Biomaterials, 2011, 32, 8364-8373.	11.4	6

#	Article	IF	CITATIONS
199	Cystone® for 1Âyear did not change urine chemistry or decrease stone burden in cystine stone formers. Urological Research, 2011, 39, 197-203.	1.5	15
200	Key role of alkaline phosphatase in the development of human-derived nanoparticles in vitro. Acta Biomaterialia, 2011, 7, 1339-1345.	8.3	16
201	Infection-Related Kidney Stones. Clinical Reviews in Bone and Mineral Metabolism, 2011, 9, 218-228.	0.8	1
202	Relative Performance of the MDRD and CKD-EPI Equations for Estimating Glomerular Filtration Rate among Patients with Varied Clinical Presentations. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1963-1972.	4.5	142
203	Eosinophiluria is common among patients after ileal conduit surgery. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1869-71.	2.3	1
204	Importance of Cystatin C Assay Standardization. Clinical Chemistry, 2011, 57, 1209-1211.	3.2	26
205	Cardiac Abnormalities in Primary Hyperoxaluria. Circulation Journal, 2010, 74, 2403-2409.	1.6	61
206	Risk Factors for CKD in Persons With Kidney Stones: A Case-Control Study in Olmsted County, Minnesota. American Journal of Kidney Diseases, 2010, 55, 61-68.	1.9	92
207	Proteomic evaluation of biological nanoparticles isolated from human kidney stones and calcified arteries. Acta Biomaterialia, 2010, 6, 4065-4072.	8.3	22
208	Kidney Stones Associate with Increased Risk for Myocardial Infarction. Journal of the American Society of Nephrology: JASN, 2010, 21, 1641-1644.	6.1	191
209	lothalamate Quantification by Tandem Mass Spectrometry to Measure Glomerular Filtration Rate. Clinical Chemistry, 2010, 56, 568-574.	3.2	23
210	Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney International, 2010, 78, 1178-1185.	5.2	128
211	Characterization of biofilm formed by human-derived nanoparticles. Nanomedicine, 2009, 4, 931-941.	3.3	17
212	Quantification of Urinary Albumin by Using Protein Cleavage and LC-MS/MS. Clinical Chemistry, 2009, 55, 1100-1107.	3.2	66
213	Kidney Stones and the Risk for Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 804-811.	4.5	296
214	Systemic injection of planktonic forms of mammalian-derived nanoparticles alters arterial response to injury in rabbits. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H1434-H1441.	3.2	17
215	Rhus verniciflua Stokes prevents cisplatin-induced cytotoxicity and reactive oxygen species production in MDCK-I renal cells and intact mice. Phytomedicine, 2009, 16, 188-197.	5.3	61
216	1,2,3,4,6-penta-O-galloyl-beta-d-glucose attenuates renal cell migration, hyaluronan expression, and crystal adhesion. European Journal of Pharmacology, 2009, 606, 32-37.	3.5	17

John C Lieske

#	Article	IF	CITATIONS
217	Current Issues in Measurement and Reporting of Urinary Albumin Excretion. Clinical Chemistry, 2009, 55, 24-38.	3.2	298
218	Biofilm formation by biologic nanoparticles may require extracellular RNA and intact ribosomal function. FASEB Journal, 2009, 23, 817.8.	0.5	0
219	Biologic Nanoparticles Calcify and Form Bacteriaâ€like Biofilm In Vitro. FASEB Journal, 2009, 23, 593.14.	0.5	0
220	Use of Sevelamer Hydrochloride as an Oxalate Binder. Journal of Urology, 2008, 179, 1407-1410.	0.4	27
221	Nephrolithiasis After Bariatric Surgery for Obesity. Seminars in Nephrology, 2008, 28, 163-173.	1.6	54
222	Can biologic nanoparticles initiate nephrolithiasis?. Nature Clinical Practice Nephrology, 2008, 4, 308-309.	2.0	11
223	Human-derived nanoparticles and vascular response to injury in rabbit carotid arteries: Proof of principle. International Journal of Nanomedicine, 2008, 3, 243.	6.7	26
224	A Liquid Chromatography-Mass Spectrometry Method for the Quantification of Urinary Albumin using a Novel 15N-Isotopically Labeled Albumin Internal Standard. Clinical Chemistry, 2007, 53, 540-542.	3.2	47
225	Search for Microbial Signatures within Human and Microbial Calcifications Using Soft X-Ray Spectromicroscopy. Journal of Investigative Medicine, 2006, 54, 367-379.	1.6	40
226	Cell Biology of Pathologic Renal Calcification. Journal of Investigative Medicine, 2006, 54, 412-424.	1.6	66
227	Diabetes Mellitus and the Risk of Urinary Tract Stones: A Population-Based Case-Control Study. American Journal of Kidney Diseases, 2006, 48, 897-904.	1.9	122
228	Spectromicroscopy of microbial signatures within human calcifications. FASEB Journal, 2006, 20, A101.	0.5	0
229	Use of a probioitic to decrease enteric hyperoxaluria. Kidney International, 2005, 68, 1244-1249.	5.2	151
230	Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney International, 2005, 68, 1784-1792.	5.2	54
231	Renal cell adaptation to oxalate. Urological Research, 2005, 33, 340-348.	1.5	19
232	International Registry for Primary Hyperoxaluria. American Journal of Nephrology, 2005, 25, 290-296.	3.1	133
233	Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases, 2005, 1, 481-485.	1.2	157
234	Sensitive Spectrophotometric Assay for Plasma Oxalate. Clinical Chemistry, 2005, 51, 2377-2380.	3.2	39

#	Article	IF	CITATIONS
235	Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H1115-H1124.	3.2	142
236	Modulation of Proliferating Renal Epithelial Cell Affinity for Calcium Oxalate Monohydrate Crystals. Journal of the American Society of Nephrology: JASN, 2004, 15, 3052-3062.	6.1	33
237	Medical Management. Clinical Reviews in Bone and Mineral Metabolism, 2004, 2, 237-252.	0.8	1
238	The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions. Urological Research, 2004, 32, 117-123.	1.5	20
239	EXTRACT FROM HERNIARIA HIRSUTA COATS CALCIUM OXALATE MONOHYDRATE CRYSTALS AND BLOCKS THEIR ADHESION TO RENAL EPITHELIAL CELLS. Journal of Urology, 2004, 172, 1510-1514.	0.4	42
240	Whole Urinary Proteins Coat Calcium Oxalate Monohydrate Crystals to Greatly Decrease Their Adhesion to Renal Cells. Journal of Urology, 2003, 170, 221-225.	0.4	50
241	Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. Kidney International, 2001, 60, 1784-1791.	5.2	47
242	Direct nucleation of calcium oxalate dihydrate crystals onto the surface of living renal epithelial cells in culture. Kidney International, 1998, 54, 796-803.	5.2	51
243	Adhesion, internalization and metabolism of calcium oxalate monohydrate crystals by renal epithelial cells. Kidney International, 1997, 52, 1291-1301.	5.2	109
244	Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney International, 1995, 48, 501-509.	5.2	91
245	Endocytosis of Calcium Oxalate Crystals and Proliferation of Renal Tubular Epithelial Cells in a Patient with Type 1 Primary Hyperoxaluria. Journal of Urology, 1992, 148, 1517-1519.	0.4	98